Evidence map›Paper›PMID 38766831›Full record

ReviewCurrent diabetes reviews2025

Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.

Rohit Kumar Tiwari, Afza Ahmad, Muskan Chadha, Kingshuk Saha, Harshitha Verma, Kalpojit Borgohain, Ratnakar Shukla

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rohit Kumar TiwariDepartment of Clinical Research, Sharda School of Allied Health Sciences, Sharda University, Gautam Buddh Nagar, Uttar Pradesh, 201310, India.
Afza AhmadDepartment of Public Health, Dr. Giri Lal Gupta Institute of Public Health and Public Affairs, University of Lucknow, Lucknow, Uttar Pradesh, 226007, India.
Muskan ChadhaDepartment of Nutrition & Dietetics, Sharda School of Allied Health Sciences, Sharda University, Gautam Buddh Nagar, Uttar Pradesh, 201310, India.
Kingshuk SahaDepartment of Clinical Research, Sharda School of Allied Health Sciences, Sharda University, Gautam Buddh Nagar, Uttar Pradesh, 201310, India.
Harshitha VermaDepartment of Science in Biochemistry, Manasagangothri, University of Mysuru, Mysuru, 570006, Karnataka, India.
Kalpojit BorgohainDepartment of Clinical Research, Sharda School of Allied Health Sciences, Sharda University, Gautam Buddh Nagar, Uttar Pradesh, 201310, India.
Ratnakar ShuklaDepartment of Clinical Research, Sharda School of Allied Health Sciences, Sharda University, Gautam Buddh Nagar, Uttar Pradesh, 201310, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDiabetes Mellitus (DM) is a global health concern that affects millions of people globally. The present review aims to narrate the clinical guidelines and therapeutic interventions for Type 2 Diabetes Mellitus (T2DM) patients. Furthermore, the present work summarizes the ongoing phase 1/2/3 and clinical trials against T2DM.

methodsA meticulous and comprehensive literature review was performed using various databases, such as PubMed, MEDLINE, Clinical trials database (https://clinicaltrials.gov/), and Google Scholar, to include various clinical trials and therapeutic interventions against T2DM.

resultsBased on our findings, we concluded that most T2DM-associated clinical trials are interventional. Anti-diabetic therapeutics, including insulin, metformin, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), and Sodium- Glucose cotransporter-2 (SGLT-2) inhibitors are frontline therapeutics being clinically investigated. Currently, the therapeutics in phase IV clinical trials are mostly SGLT-2 inhibitors, implicating their critical contribution to the clinical management of T2DM.

conclusionDespite the success of T2DM treatments, a surge in innovative treatment options to reduce diabetic consequences and improve glycemic control is currently ongoing. More emphasis needs to be on exploring novel targeted drug candidates that can offer more sustained glycemic control.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsBlood GlucoseClinical Trials as TopicDipeptidyl-Peptidase IV InhibitorsHumansSodium-Glucose Transporter 2 InhibitorsBlood GlucoseDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorsclinical trialsDPP-4 inhibitorsGLP-1 agonistsglucose levels.SGLT-2 antagonistType 2 diabetes

Identifiers

PMID38766831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.